Progestagen-only oral contraceptives: a preliminary report of the action and clinical use of norgestrel and norethisterone.
D001943:Breast Neoplasms / Q000150:complications; D002715:Chlormadinone Acetate / Q000494:pharmacology; D003276:Contraceptives, Oral / Q000009:adverse effects*; D003338:Corpus Luteum / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D005298:Fertility / Q000187:drug effects; D005640:Follicle Stimulating Hormone / Q000037:antagonists & inhibitors; D006801:Humans; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D007986:Luteinizing Hormone / Q000037:antagonists & inhibitors; D009093:Mucus / Q000187:drug effects; D009640:Norethindrone / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology*; D009644:Norgestrel / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology*; D011247:Pregnancy; D013923:Thromboembolism / Q000139:chemically induced; D014625:Vaginal Neoplasms / Q000150:complications
D003276:Contraceptives, Oral; D008055:Lipids; D008074:Lipoproteins; D002715:Chlormadinone Acetate; D009644:Norgestrel; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D009640:Norethindrone